血清碱性成纤维生长因子在晚期NSCLC中的表达和临床价值

Prognostic value of basic fibroblast growth factor in patients with non-small cell lung cancer

目的碱性成纤维生长因子(bFGF)作为非小细胞肺癌(NSCLC)重要的血管新生因子,参与疾病的发生和发展。本研究检测bFGF在NSCLC患者血清中的表达,探讨bFGF在NSCLC患者疾病分期、治疗反应和预后中的价值。方法采用ELISA方法检测66例晚期NSCLC患者和15例健康体检者血清bFGF的表达水平,并和临床指标进行比较分析。结果 NSCLC患者血清bFGF的表达水平显著高于正常对照组(3.2vs 20.1 pg/ml,P<0.001);在治疗结束后bFGF水平逐步下降(20.1 vs 10.6 pg/ml,P<0.05);生存分析发现NSCLC患者治疗前血清bFGF水平和患者无疾病进展生存显著相关,血清bFGF>20 pg/ml患者的PFS显著短于bFGF水平较低患者(5.6月vs 9.6月,P<0.001)。结论 NSCLC患者血清bFGF水平和疾病发生发展、疾病分期和疾病生存有关,可以作为NSCLC血管新生和预后的新指标。

Objective To investigate the value of basic fibroblast growth factor（ bFGF） on clinical stage,treatment response and prognosis of patients with NSCLC. Methods The level of serum bFGF was determined in 66 advanced NSCLC patients and 15 healthy controls by ELISA. Correlation between bFGF expression and clinical data was analyzed. Results The expression of bFGF was significantly higher in NSCLC patients than the control group（ 3.2 vs 20.1 pg/ml,P〈0.001）,and it decreased gradually after the treatment（ 20.1 vs 10.6 pg/ml,P〈0.05）.The elevated expression of bFGF 〉20 pg /ml at baseline was associated with a negative prognosis and shorter progression-free survival（ PFS）（ 5. 6 mon vs 9. 6 mon,P〈0. 001）. Conclusion There is significant correlation between bFGF expression and disease development,clinical stage and survival,which can be a potential biomarker for predicting angiogenesis and prognosis.